Ana Martin-Villalba

Ana Martin-Villalba

Auto-generated profile, based on publicly available information

Ana Martin-Villalba

Molecular Neurobiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in Cell Stem Cell
Verified
Journal Article
Closed access
ELEnric Llorens-Bobadilla
Enric Llorens-Bobadilla
SZSheng Zhao
Sheng Zhao
ABAvni Baser
Avni Baser
GSGonzalo Saiz-Castro
Gonzalo Saiz-Castro
KZKlara Zwadlo
Klara Zwadlo
AMAna Martin-Villalba
Ana Martin-Villalba

22 April 2002 in Nature Genetics
Verified
Journal Article
Closed access
TMTheo Mantamadiotis
Theo Mantamadiotis
TLThomas Lemberger
Thomas Lemberger
SBSusanne C. Bleckmann
Susanne C. Bleckmann
HKHeidrun Kern
Heidrun Kern
OKOliver Kretz
Oliver Kretz
GSGünther Schütz
Günther Schütz

1 May 1999 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ASArmin Schneider
Armin Schneider
AMAna Martin-Villalba
Ana Martin-Villalba
FWFalk Weih
Falk Weih
JVJohannes Vogel
Johannes Vogel
TWThomas Wirth
Thomas Wirth
MSMarkus Schwaninger
Markus Schwaninger

1 March 2019 in Cell
Verified
Journal Article
Closed access
GKGeorgios Kalamakis
Georgios Kalamakis
DBDaniel Brüne
Daniel Brüne
SRSrikanth Ravichandran
Srikanth Ravichandran
JBJan Bolz
Jan Bolz
WFWenqiang Fan
Wenqiang Fan
AMAna Martin-Villalba
Ana Martin-Villalba

15 May 1999 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
AMAna Martin-Villalba
Ana Martin-Villalba
IHIngrid Herr
Ingrid Herr
IJIrmela Jeremias
Irmela Jeremias
MHMichael Hahne
Michael Hahne
RBRoland Brandt
Roland Brandt
KDKlaus-Michael Debatin
Klaus-Michael Debatin
Programmed cell death plays an important role in the neuronal degeneration after cerebral ischemia, but the underlying mechanisms are not fully understood. Here we examined,in vivoandin vitro, whether ischemia-induced neuronal death involves death-inducing ligand/receptor systems such as CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). After reversible middle cerebral artery occlusion in adult rats, both CD95 ligand and TRAIL were expressed in the apoptotic areas of the postischemic brain. Further recombinant CD95 ligand and TRAIL proteins induced apoptosis in primary neurons and neuron-like cellsin vitro. The immunosuppressant FK506, which most effectively protects against ischemic neurodegeneration, prevented postischemic expression of these death-inducing ligands bothin vivoandin vitro. FK506 also abolished phosphorylation, but not expression, of the c-Jun transcription factor involved in the transcriptional control of CD95 ligand. Most importantly, inlprmice expressing dysfunctional CD95, reversible middle cerebral artery occlusion resulted in infarct volumes significantly smaller than those found in wild-type animals. These results suggest an involvement of CD95 ligand and TRAIL in the pathophysiology of postischemic neurodegeneration and offer alternative strategies for the treatment of cardiovascular brain disease.

5 October 2014 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
VGVeselin Grozdanov
Veselin Grozdanov
CBCorinna Bliederhaeuser
Corinna Bliederhaeuser
WRWolfgang P. Ruf
Wolfgang P. Ruf
VRValerie Roth
Valerie Roth
KFKathrin Fundel-Clemens
Kathrin Fundel-Clemens
KDKarin M. Danzer
Karin M. Danzer
Despite extensive effort on studying inflammatory processes in the CNS of Parkinson’s disease (PD) patients, implications of peripheral monocytes are still poorly understood. Here, we set out to obtain a comprehensive picture of circulating myeloid cells in PD patients. We applied a human primary monocyte culture system and flow cytometry-based techniques to determine the state of monocytes from PD patients during disease. We found that the classical monocytes are enriched in the blood of PD patients along with an increase in the monocyte-recruiting chemoattractant protein CCL2. Moreover, we found that monocytes from PD patients display a pathological hyperactivity in response to LPS stimulation that correlates with disease severity. Inflammatory pre-conditioning was also reflected on the transcriptome in PD monocytes using next-generation sequencing. Further, we identified the CD95/CD95L as a key regulator for the PD-associated alteration of circulating monocytes. Pharmacological neutralization of CD95L reverses the dysregulation of monocytic subpopulations in favor of non-classical monocytes. Our results suggest that PD monocytes are in an inflammatory predisposition responding with hyperactivation to a “second hit”. These results provide the first direct evidence that circulating human peripheral blood monocytes are altered in terms of their function and composition in PD patients. This study provides insights into monocyte biology in PD and establishes a basis for future studies on peripheral inflammation.